HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Switzerland Approves Raft Of Rx-To-OTC Switches

Executive Summary

Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.

You may also be interested in...



Switzerland Reclassifies Rx Drugs For Migraine And Pain

Switzerland has added treatments for migraine and acute pain to the list of Rx drugs permitted for sale without prescription in pharmacy.

Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway

Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.

Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

Swiss medicines authority, Swissmedic, rules that hundreds of non-prescription medicines are safe to be purchased outside pharmacy, following the completion of its review of the country's medicines classification system.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel